In a rare move, the FDA has publicly accused US biotech CytoDyn of misrepresenting clinical trial results for leronlimab, an antibody being developed for COVID-19. It's not uncommon for drug ...

Nader Pourhassan, who led CytoDyn until in 2022, had drawn widespread attention — and scrutiny — for his relentless promotion ...

Dr. Jacob Lalezari, CEO, and Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology, to lead CytoDyn group in attendance VANCOUVER, Washington, April 29, 2025 (GLOBE NEWSWIRE) -- ...

Today, shares of CytoDyn Inc. (OTCQB: CYDY) are on a tear as the biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced ...

leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Actin ...

CytoDyn has received FDA clearance to initiate a Phase II study of leronlimab in patients with relapsed or refractory micro-satellite stable colorectal cancer (CRC) (NCT06699835). The drug ...